Latest Conference Articles

The study looked at dapagliflozin's benefits in the acute illness setting, specifically organ protection, according to Mikhail N. Kosiborod, MD, vice president of Research at Saint Luke's Health System.

The Dapagliflozin in Respiratory Failure in Patients With COVID-19 trial is the first phase 3 study to examine whether this SGLT2 inhibitor, which has proven effective for multiple chronic conditions, might be similarly useful in an acute setting.

A pediatric infectious disease expert reviewed some developments in the vaccine development pipeline, especially new efforts targeting infant health through maternal immunizations.

Patients with hypertrophic cardiomyopathy (HCM) had symptomatic, functional, and structural biomarker changes over the course of a little more than 6 months, explained Jay Edelberg, MD, PhD, head of Heart Failure and Cardiomyopathy Development at Bristol Myers Squibb.

ADAPTABLE was an opportunity to accomplish a large-scale study in a generalizable manner: directly involve patients, partner with them, and cocreate the program, noted Schuyler Jones, MD, associate professor of medicine at Duke University.

The investigational drug for obstructive hypertrophic cardiomyopathy is in front of FDA, with an approval target date of January 28, 2022.

Farrah Kheradmand, MD, gives an overview of her research on the mechanisms of vaping-associated lung injuries.

Results presented at the American College of Cardiology's 70th Scientific Session show most patients prefer a smaller dose and are more likely to stick with it.

Lou Garrison, PhD, professor emeritus in the Department of Pharmacy, University of Washington, previews the layout of the virtual 2021 ISPOR annual conference and the myriad of upcoming discussions.

Panelists of a session at the Pharmacy Quality Alliance 2021 Annual Meeting explore how shared decision-making and patient decision aids can promote appropriate care and treatment adherence, as well as lower cost and utilization of health care services.

It has been really tricky to identify and appropriately treat vaping-associated lung diseases in the time of COVID-19, said Laura Crotty Alexander, MD, ATSF.

Fourteen months after the American College of Cardiology (ACC) switched its 17,000-person meeting to a virtual format on short notice, the meeting will be online May 15-17 for the second year. The 70th Scientific Session will feature 25 late-breaking clinical trials, emphasizing treatment of heart failure and the right aspirin dose for prevention of secondary cardiovascular disease.

The 4-day annual meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research—will cover a wide range of topics. Here are 5 themes to keep an eye out for.

We’re going to celebrate and refocus on the science, reflect and share lessons learned from the pandemic, and really engage our audience in discussions that cover care guidelines and nontraditional pathways of care, said Pamela Bowe Morris, MD, chair of ACC.21.

Panelists of a session at the Pharmacy Quality Alliance (PQA) 2021 Annual Meeting discuss challenges contributing to health inequities in patient care, particularly medication use quality, as well as efforts to improve these issues.

Understanding that there is a third type of heart failure will further our understanding of the disease, noted Clyde W. Yancy, MD, MSc, chief of cardiology and vice dean for diversity and inclusion at Northwestern University's Feinberg School of Medicine.

A novel biologic for severe asthma reduced exacerbations by 56%, according to a study published Wednesday in The New England Journal of Medicine.

Vaping and other key respiratory issues, such as asthma, COPD, and new biologics, join COVID-19 on the ATS 2021 International Conference agenda.

Joe Zein, MD, PhD, discusses what to expect from his talk on sex differences in asthma at this year's American Thoracic Society (ATS) meeting.

There is a persistent gap in heart failure care regarding administration of life-saving therapies outlined in clinical practice guidelines and consensus documents, noted James Jacuzzi, MD, of Harvard Medical School and an ACC trustee.

Laura Crotty Alexander, MD, ATSF, outlines her presentation on e-cigarette or vaping product use-associated lung injury (EVALI) and other vaping diseases in the time of COVID-19 and beyond.

Michelle M Cloutier, MD, is professor emerita at UCONN Health in Farmington, Connecticut, and chair of the National Asthma Education and Prevention Program (NAEPP) Coordinating Committee Expert Panel Working Group.

Administrative claims data in oncology often lack sufficient information to conduct postmarketing comparison studies of biosimilars with their reference product, suggesting that other sources are needed to answer critical research questions.

Both studies were featured during the American College of Cardiology's annual briefing on results for consumers. They will be presented during the 70th Scientific Session, which is set for May 15-17, 2021.

There is likely not directly infectious replicating skin in a condition known as "COVID toes," and that’s important to reassure patients, said Christine Ko, MD, professor of dermatology and pathology at Yale University.

Patients want better control of their atopic dermatitis, and we don’t want them to acquiesce to their disease, explained Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital-San Diego.

With immunosuppression, self-regulatory mechanisms may start to decrease, and these are the patients who develop skin cancers more frequently, said Rajiv Nijhawan, MD, UT Southwestern Medical Center.

Posters presented at the American Academy of Dermatology Virtual Meeting Experience show ruxolitinib cream was effective at treating atopic dermatitis (AD) regardless of previous treatments and in patients with more severe disease.